Efficacy and toxicity of particle radiotherapy in WHO grade II and grade III meningiomas: a systematic review

Wu, Adela; Jin, Michael C.; Meola, Antonio; Wong, Henry Sung Ching; Chang, Steven D.

doi:10.3171/2019.3.focus1967

Cited by 16 publications

(8 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because there is a lack of standardized treatment for resected grade 2 meningiomas, performing noninvasive risk stratification prior to adjuvant therapies is highly desirable. Even after surgical resection, patients at high-risk for tumor recurrence can be considered for intensified adjuvant therapies, and patients at low-risk for tumor recurrence can be spared from experiencing the possible neurotoxicities of ART [ 38 ]. Several previous studies investigated clinical prognostic factors for grade 2 meningiomas, which included age, sex, extent of resection, tumor invasiveness (i.e., brain or bone invasion), and higher MIB-1 labeling index [ 39 , 40 ].…”

Section: Discussionmentioning

confidence: 99%

An interpretable radiomics model to select patients for radiotherapy after surgery for WHO grade 2 meningiomas

et al. 2022

View full text Add to dashboard Cite

Objectives This study investigated whether radiomic features can improve the prediction accuracy for tumor recurrence over clinicopathological features and if these features can be used to identify high-risk patients requiring adjuvant radiotherapy (ART) in WHO grade 2 meningiomas. Methods Preoperative magnetic resonance imaging (MRI) of 155 grade 2 meningioma patients with a median follow-up of 63.8 months were included and allocated to training (n = 92) and test sets (n = 63). After radiomic feature extraction (n = 200), least absolute shrinkage and selection operator feature selection with logistic regression classifier was performed to develop two models: (1) a clinicopathological model and (2) a combined clinicopathological and radiomic model. The probability of recurrence using the combined model was analyzed to identify candidates for ART. Results The combined clinicopathological and radiomics model exhibited superior performance for the prediction of recurrence compared with the clinicopathological model in the training set (area under the curve [AUC] 0.78 vs. 0.67, P = 0.042), which was also validated in the test set (AUC 0.77 vs. 0.61, P = 0.192). In patients with a high probability of recurrence by the combined model, the 5-year progression-free survival was significantly improved with ART (92% vs. 57%, P = 0.024), and the median time to recurrence was longer (54 vs. 17 months after surgery). Conclusions Radiomics significantly contributes added value in predicting recurrence when integrated with the clinicopathological features in patients with grade 2 meningiomas. Furthermore, the combined model can be applied to identify high-risk patients who require ART.

show abstract

Section: Discussionmentioning

confidence: 99%

An interpretable radiomics model to select patients for radiotherapy after surgery for WHO grade 2 meningiomas

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In addition to photon RT, particle-based RT using either protons, carbon ions or boron neutron capture, has also been evaluated, often in the reirradiation setting. Control rates are promising and toxicities generally tolerable [ 126 , 127 , 128 ]. Currently, the decision to use particle RT is made on a case-by-case basis.…”

Section: Clinical Managementmentioning

confidence: 99%

Clinical Management of Supratentorial Non-Skull Base Meningiomas

Adekanmbi

Youngblood

Karras

et al. 2022

Cancers

View full text Add to dashboard Cite

Supratentorial non-skull base meningiomas are the most common primary central nervous system tumor subtype. An understanding of their pathophysiology, imaging characteristics, and clinical management options will prove of substantial value to the multi-disciplinary team which may be involved in their care. Extensive review of the broad literature on the topic is conducted. Narrowing the scope to meningiomas located in the supratentorial non-skull base anatomic location highlights nuances specific to this tumor subtype. Advances in our understanding of the natural history of the disease and how findings from both molecular pathology and neuroimaging have impacted our understanding are discussed. Clinical management and the rationale underlying specific approaches including observation, surgery, radiation, and investigational systemic therapies is covered in detail. Future directions for probable advances in the near and intermediate term are reviewed.

show abstract

“…Recently Wu et al published a review of the results of particle radiotherapy for WHO grade II (AM) and grade III meningiomas (MM) in 11 articles including 240 patients [39]. LCR at five years or at the end of the follow-up (median 145 months) ranged from 46.7 to 86%.…”

Section: Non-benign Meningiomamentioning

confidence: 99%

Stereotactic Radiosurgery and Stereotactic Radiotherapy for Malignant Skull Base Tumors

Mori¹,

Kida²,

Matsushita³

et al. 2020

Cureus

View full text Add to dashboard Cite

The role of stereotactic radiosurgery/stereotactic radiotherapy (SRS/SRT) for malignant skull base tumors was summarized and discussed. The treatment of skull base tumors remains challenging. Their total resection is often difficult. SRS/SRT is one useful treatment option for residual or recurrent tumors after surgical resection in cases of primary skull base tumors. If skull base metastasis and skull base invasion are relatively localized, they can be candidates for SRS/SRT. Low rates of cervical lymph node involvement in early-stage (N0M0, no lymph node involvement or distant metastasis) nasal and paranasal carcinomas (NpNCa) and external auditory canal carcinomas (EACCa) have been reported in the literature. Such cases might be good candidates for SRS/SRT as the initial therapy. We previously reported the results of SRS/SRT for various malignant extra-axial skull base tumors. In addition, treatment results of early-stage head and neck carcinomas were summarized. Those of our data and those of other reported series were reviewed here to clarify the usefulness of SRS/SRT for malignant extraaxial skull base tumors.

show abstract

Efficacy and toxicity of particle radiotherapy in WHO grade II and grade III meningiomas: a systematic review

Cited by 16 publications

References 64 publications

An interpretable radiomics model to select patients for radiotherapy after surgery for WHO grade 2 meningiomas

An interpretable radiomics model to select patients for radiotherapy after surgery for WHO grade 2 meningiomas

Clinical Management of Supratentorial Non-Skull Base Meningiomas

Stereotactic Radiosurgery and Stereotactic Radiotherapy for Malignant Skull Base Tumors

Contact Info

Product

Resources

About